Supernus Pharmaceuticals (SUPN)$48.21
Currency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Supernus Pharmaceuticals (SUPN).
DCF ready
Valuation
56.4x
EV/FCF, 1.8% FCF yield
Quality
-3.6%
ROIC, 6.4% FCF margin
Growth
6.7%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 1.9x current ratio
Superinvestors
1
Top: Third Avenue Management (1.3%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- P/FCF is elevated at 59.2x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for SUPN.
Grade D
34
/ 100
Financial Charts
No financial data available for SUPN (annual).
1 superinvestors own SUPN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Third Avenue Management Third Avenue Management | 152,724 | $8M | 1.28% | 0.0% |